HOME >> MEDICINE >> NEWS
New rheumatoid arthritis drug developed at UCSD promises improved treatment options

Researchers at the University of California, San Diego (UCSD) School of Medicine have announced successful completion of Phase II clinical trials of a novel drug for the treatment of rheumatoid arthritis (RA), one that works without suppressing the patient's immune system.

Salvatore Albani, M.D., Ph.D, professor of medicine and pediatrics and Director of the Translational Research Unit of the Clinical Investigation Institute (CII) at the UCSD School of Medicine, recently presented a summary of the findings at the "Frontiers of Clinical Investigation Symposium." The symposium, sponsored by the CII and Nature Medicine, was held in La Jolla, California in September.

The new drug, dnaJP1, is a peptide derived from a naturally occurring protein, dnaJ, which generates inflammation in RA patients, whose inflammatory-control mechanisms are impaired. The impairment causes the body's T cells which trigger inflammation to kill and clear foreign pathogens in the body to attack the body's own tissues.

"In essence, we re-educated the immune system T cells to be tolerant of the dnaJP1 amino acid sequence, which would usually contribute to inflammation in rheumatoid arthritis patients," Albani said.

DnaJP1 works by resetting the ability of the patient's immune system to tolerate dnaJ, thus transforming a potentially damaging trigger into a tool for controlling the disease. Oral ingestion of dnaJP1 is key, because the mucosal immune system found in the gut has the ability to "teach" the body to view a protein as one that isn't dangerous or foreign. Much as food is ingested into the body and not rejected, the body tolerates dnaJP1.

Current medications for treating RA range from anti-inflammatory drugs, such as aspirin, to corticosteroids and medicines that alleviate symptoms by suppressing or killing the body's immune response, basically crippling the body's ability to defend itself against other infectious diseases or cancer.


'"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
14-Oct-2005


Page: 1 2 3

Related medicine news :

1. Green tea compound may be a therapy for people with rheumatoid arthritis
2. The link between rheumatoid arthritis and cancer
3. Predicting the risk of rheumatoid arthritis for early arthritis patients
4. Women with rheumatoid arthritis have significantly less chance of remission than men
5. New study reveals postcode lottery for rheumatoid arthritis treatment
6. Cancer drug may be remedy for rheumatoid arthritis, Stanford study finds
7. A new approach to rheumatoid arthritis
8. Increased odds of rheumatoid arthritis in women smokers without genetic risk factor
9. New research addresses taboos around the impact of rheumatoid arthritis on patients sex lives
10. New evidence shows MabThera inhibits joint damage in patients with rheumatoid arthritis
11. PTPN22 gene associated with both susceptibility and disease progression in rheumatoid arthritis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... ... 2017 , ... According to a new study by NCPA Senior Fellow John ... the rules Congress has directed the CBO to follow. The CBO itself previously recognized ... Yet, it estimates a reduction in employer-based coverage due to the GOP reform, which ...
(Date:3/24/2017)... Sedona, Arizona (PRWEB) , ... March 24, 2017 ... ... Shamangelic Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Jorge Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, ... Claims Litigation seminar in Chicago, Illinois. She will present on: , Filing ... litigated under ERISA involve claims for long-term disability benefits. This session will ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... the year of enhancements, upgrading their training and leads programs. , In February, ... Reserved for elite sales agents, Performance Partners is designed to teach how to ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “Vintage and Harvest ... retired minister and college Bible teacher residing in North Carolina with his wife, Anna ... have blessed them with six grandchildren. David is also the author of “Shadow and ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... SEATTLE , March 27, 2017  PhaseRx, ... treatments for life-threatening inherited liver diseases in children, ... and full year ended December 31, 2016 and ... "PhaseRx continued to make progress during ... of positive results from our non-human primate safety study, ...
(Date:3/27/2017)... SAN DIEGO , March 27, 2017 ... biopharmaceutical company focused on developing novel, small molecule drugs across ... Company,s President and Chief Executive Officer, will present a corporate ... April 4 at 3:40pm ET.  The conference will take place ... in New York , NY.  ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets ... Market, 2017-2027" report to their offering. ... The Cell Therapy Manufacturing ... growing market of cell therapy manufacturing and focuses both on ... These therapies are anticipated to emerge as viable alternatives to ...
Breaking Medicine Technology:
Cached News: